Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VIR Vir Biotechnology, Inc.

Trading 04-13 12:35:06 EDT

9.33

-0.17

-1.84%

High9.58	Low9.12	Vol518.96K
Open9.12	D1 Closing9.50	Amplitude4.89%
Mkt Cap1.46B	Tradable Cap997.77M	Total Shares157.00M
T/O4.84M	T/O Rate0.49%	Tradable Shares107.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VIR","market":"US","secType":"STK","nameCN":"Vir Biotechnology, Inc.","latestPrice":9.325,"timestamp":1776098104272,"preClose":9.5,"halted":0,"volume":518958,"delay":0,"changeRate":-0.018421052631579022,"floatShares":107000000,"shares":157000000,"eps":-3.161894,"marketStatus":"Trading","change":-0.175,"latestTime":"04-13 12:35:06 EDT","open":9.115,"high":9.58,"low":9.115,"amount":4842384.902487,"amplitude":0.048947,"askPrice":9.33,"askSize":141,"bidPrice":9.32,"bidSize":222,"shortable":3,"etf":0,"ttmEps":-3.161894,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776110400000},"marketStatusCode":2,"adr":0,"listingDate":1570766400000,"exchange":"NASDAQ","adjPreClose":9.5,"preHourTrading":{"tag":"盘前","latestPrice":9.1,"preClose":9.5,"latestTime":"09:29 EDT","volume":6047,"amount":56411.43501,"timestamp":1776086999999,"change":-0.4,"changeRate":-0.042105,"amplitude":0.052632},"postHourTrading":{"tag":"盘后","latestPrice":9.49,"preClose":9.5,"latestTime":"18:38 EDT","volume":9053,"amount":86001.63,"timestamp":1775860727327,"change":-0.01,"changeRate":-0.001053,"amplitude":0.001053},"volumeRatio":0.604702,"impliedVol":0.8306,"impliedVolPercentile":0.628},"requestUrl":"/m/hq/s/VIR","defaultTab":"news","newsList":[{"id":"2627814458","title":"Vir doses first patient in Phase 1 VIR-5500 expansion trial for metastatic prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627814458","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627814458?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:08","pubTimestamp":1776082111,"startTime":"0","endTime":"0","summary":"Vir began enrollment in Phase 1 dose-expansion cohorts for VIR-5500, a PSMA-targeted T-cell engager, following dosing of first patient in metastatic prostate cancer study NCT05997615.Phase 1 results were already presented at 2026 ASCO Genitourinary Cancers Symposium, supporting a favorable safety profile and early signs of anti-tumor activity.Expansion cohort will assess whether VIR-5500 can deliver meaningful responses in late-line metastatic castration-resistant prostate cancer.Combination dose escalation with enzalutamide continues, with first patients in combination expansion cohorts expected over coming months.Company plans to move into pivotal Phase 3 trials in 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnolog","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL4GCPLf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4568","VIR","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627430067","title":"Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-Expansion Cohorts Evaluating Psma-Targeted, Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 in Patients With Metastatic Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627430067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627430067?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:05","pubTimestamp":1776081900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUABL18JT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4535","BK4585","VIR","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627430065","title":"Vir Biotechnology Inc - Vir-5500 Combination Cohorts to Begin Soon; Phase 3 Trials Planned for 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2627430065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627430065?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:05","pubTimestamp":1776081900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUABL18JT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VIR","BK4535","BK4585","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626110144","title":"Vir Biotechnology CMO Mark Eisner to step down April 24","url":"https://stock-news.laohu8.com/highlight/detail?id=2626110144","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626110144?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:01","pubTimestamp":1775851303,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Chief Medical Officer Mark Eisner will step down effective April 24, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL9wFLzC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4535","BK4568","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156527754","title":"Trump Will Impose 100% Tariff on Some Patented Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1156527754","media":"Tiger Newspress","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156527754?lang=en_us&edition=fundamental","pubTime":"2026-04-03 07:16","pubTimestamp":1775171812,"startTime":"0","endTime":"0","summary":"The Trump administration will impose tariffs of as much as 100% on certain imported medicines, albeit with several major exemptions, a maneuver to pressure drugmakers to manufacture more in the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"4e63e9b5baa83146ad37e2bf910d1394","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY","REGN","MRNA","VERU","PFE","SNY","GSK","GILD","NVS","JNJ","BIIB","MRK","BNTX","NVAX","VIR","LLY","ABBV","AMGN","ABT","NVO","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624500388","title":"Vir director Vicki L. Sato disposes Vir Biotechnology shares worth $0.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624500388","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624500388?lang=en_us&edition=fundamental","pubTime":"2026-04-02 22:47","pubTimestamp":1775141251,"startTime":"0","endTime":"0","summary":"Vir director Vicki L. Sato sold 22,000 shares on April 1, 2026 at USD 9.07 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL7GB4FG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir director Vicki L. Sato disposes Vir Biotechnology shares worth $0.2 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4585","VIR","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622252013","title":"Vir Biotechnology SVP and Chief Accounting Officer Brent Sabatini disposes of USD 70,332 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2622252013","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622252013?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:36","pubTimestamp":1774384582,"startTime":"0","endTime":"0","summary":"Brent Sabatini, SVP and Chief Accounting Officer at Vir Biotechnology, reported a sale of 7,711 shares of common stock on 03/23/2026.The shares were sold at USD 9.12 per share.Following the transaction, Sabatini reported direct ownership of 61,902 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL5KxnTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir Biotechnology SVP and Chief Accounting Officer Brent Sabatini disposes of USD 70,332 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4585","BK4568","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617612665","title":"Vir Biotechnology Inc - Appoints Marianne De Backer as President in Addition to CEO on March 4, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617612665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617612665?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:41","pubTimestamp":1772660490,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS2BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4139","VIR","BK4568","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617429566","title":"Vir Biotech Names CEO Marianne De Backer President","url":"https://stock-news.laohu8.com/highlight/detail?id=2617429566","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617429566?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:03","pubTimestamp":1772658204,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. said its board appointed Chief Executive Officer Marianne De Backer to the additional role of President, effective March 4, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL85JRlc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4568","BK4585","VIR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616537340","title":"Vir Biotechnology Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616537340","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616537340?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:11","pubTimestamp":1772626260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VIR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2026 07:11 ET (12:11 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4568","BK4585","VIR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616534348","title":"Vir Biotechnology price target raised to $20 from $15 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2616534348","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616534348?lang=en_us&edition=fundamental","pubTime":"2026-03-04 19:16","pubTimestamp":1772622961,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Vir Biotechnology (VIR) to $20 from $15 and keeps a Buy rating on the shares. The firm says the “...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-price-target-raised-to-20-from-15-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-price-target-raised-to-20-from-15-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","VIR","BK4139","BK4568","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616327740","title":"Vir Biotechnology Director Vicki L Sato Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616327740","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616327740?lang=en_us&edition=fundamental","pubTime":"2026-03-04 01:10","pubTimestamp":1772557846,"startTime":"0","endTime":"0","summary":"Vicki L. Sato, a director of Vir Biotechnology, Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDLFZqst:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir Biotechnology Director Vicki L Sato Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4568","VIR","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614748210","title":"Vir Biotechnology EVP and General Counsel Vanina de Verneuil Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614748210","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614748210?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:58","pubTimestamp":1772143089,"startTime":"0","endTime":"0","summary":"Vanina de Verneuil, EVP, General Counsel and Corporate Secretary of Vir Biotechnology, Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL8bZJ1T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir Biotechnology EVP and General Counsel Vanina de Verneuil Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","BK4585","VIR","BK4568"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2614426620","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2614426620","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614426620?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:22","pubTimestamp":1772112120,"startTime":"0","endTime":"0","summary":"Procept BioRobotics  shares were down 24% in recent Thursday premarket activity, a day after the company posted a wider Q4 net loss and BofA Securities downgraded the company's stock to underperform from neutral.The Trade Desk  stock was down 17%, a day after the company issued lower-than-expected Q1 revenue guidance.Vir Biotechnology  shares were 16% lower after the company said overnight it priced an underwritten offering of about 17.6 million of its common shares for expected gross proceeds of $150 million.Larimar Therapeutics  stock was down 11%, a day after the company said it priced an upsized public offering of 20 million common shares at $5 each to raise $100 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1720051017.SGD","BK4082","BK4613","BK4009","BK4585","VIR","TTD","BK4023","LRMR","LU1548497426.USD","LU1720051108.HKD","BK4548","LU2357305700.SGD","BK4535","BK4139","LU2324357040.USD","TTDU","BK4568","BK4588","BK4528","PRCT","LU0348723411.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2614043829","title":"BUZZ-Vir Biotech drops after $150 mln stock sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2614043829","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614043829?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:37","pubTimestamp":1772105871,"startTime":"0","endTime":"0","summary":"BUZZ-Vir Biotech drops after $150 mln stock sale** Vir Biotechnology's VIR.O shares down 10% premarket at $9 after $150 mln follow-on priced** San Francisco, California-based firm late Weds announced ~17.6 mln shares at $8.50, a 15% discount to last sale** VIR shares finished up ~5% at $10 on Weds following 28% gain on Tues after co posted Q4 rev beat and said it's collaborating to develop its prostate cancer experimental drug with Japan's Astellas 4503.T** After the bell Tues, co announced $200 mln stock offering** It intends to use net offering proceeds to fund its portion of global clinical development costs, and potential portion of commercial launch costs for the drug, VIR-5500, under the Astellas agreement, among other purposes, per the offering prospectus** Goldman Sachs, Leerink, Evercore and Barclays joint bookrunners** Co has ~139.5 mln shares outstanding** Through Weds, stock up 66% YTD** All 10 analysts covering VIR are bullish and their median PT is $18, per LSEG data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL6N3ZM0RI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1804176565.USD","LU2237443622.USD","LU0061475181.USD","LU2237443465.HKD","LU0251142724.SGD","LU1868836914.USD","LU0048573561.USD","LU2237438978.USD","BK4585","LU1868836757.USD","LU1868836591.USD","IE00BFXG1179.USD","EVR","IE00BSNM7G36.USD","LU1868837136.USD","LU1894683348.USD","BK4550","LU2471134523.USD","LU0251131958.USD","BK4127","LU2237443895.HKD","LU2265009873.SGD","BK4533","LU2237443978.SGD","IE0004091025.USD","LU1868837300.USD","LU0096364046.USD","LU1668664300.SGD","LU2237443382.USD","BK4139","LU2471134879.HKD","IE0004086264.USD","BK4516","LU2750360641.GBP","LU0742534661.SGD","IE00B19Z3581.USD","BK4535","LU0345770993.USD","BK4552","LU1791807156.HKD","LU0345770308.USD","BK4504","LU2750360997.AUD","IE00B19Z3B42.SGD","IE0034235188.USD","GSX","LU2237443549.SGD","VIR","IE0002270589.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1141826197","title":"Stock Track | Vir Biotechnology Plunges 7.80% in Pre-market After Pricing Public Offering at $8.50 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1141826197","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141826197?lang=en_us&edition=fundamental","pubTime":"2026-02-26 17:05","pubTimestamp":1772096729,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. (VIR) saw its shares plummet 7.80% in pre-market trading on Thursday.The sharp decline follows the company's announcement that it has priced a public offering of its common...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VIR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1139535069","title":"Stock Track | Vir Biotechnology Plunges 5% After Pricing Public Offering at $8.50 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1139535069","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139535069?lang=en_us&edition=fundamental","pubTime":"2026-02-26 12:02","pubTimestamp":1772078570,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. (VIR) experienced a significant decline of 5.00% during the trading session, marking a notable 24-hour plunge for the biotech stock.The sharp drop follows the company's...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VIR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2614674460","title":"BRIEF-Vir Biotechnology Announces Pricing Of Public Offering Of Common Stock At $8.50 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2614674460","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614674460?lang=en_us&edition=fundamental","pubTime":"2026-02-26 11:31","pubTimestamp":1772076716,"startTime":"0","endTime":"0","summary":"BRIEF-Vir Biotechnology Announces Pricing Of Public Offering Of Common Stock At $8.50 Per ShareFeb 25 (Reuters) - Vir Biotechnology Inc VIR.O:VIR BIOTECHNOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUAWM4LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4568","BK4585","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614067490","title":"Vir Biotechnology Inc - Prices Public Offering at $8.50 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2614067490","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614067490?lang=en_us&edition=fundamental","pubTime":"2026-02-26 11:31","pubTimestamp":1772076660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUAWM4LY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4585","BK4568","BK4139","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614031177","title":"Vir Biotechnology Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2614031177","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614031177?lang=en_us&edition=fundamental","pubTime":"2026-02-26 00:24","pubTimestamp":1772036640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VIR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2026 11:24 ET (16:24 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4139","BK4535","BK4585","BK4568"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vir.bio","stockEarnings":[{"period":"1week","weight":0.0486},{"period":"1month","weight":-0.0326},{"period":"3month","weight":0.6239},{"period":"6month","weight":0.6379},{"period":"1year","weight":0.7992},{"period":"ytd","weight":0.5755}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.442895},{"month":2,"riseRate":0.428571,"avgChangeRate":0.063735},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.106207},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.066673},{"month":5,"riseRate":0.666667,"avgChangeRate":0.058008},{"month":6,"riseRate":0.5,"avgChangeRate":0.020036},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.044477},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.0277},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.115495},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03118},{"month":11,"riseRate":0.857143,"avgChangeRate":0.105555},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.058058}],"exchange":"NASDAQ","name":"Vir Biotechnology, Inc.","nameEN":"Vir Biotechnology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vir Biotechnology, Inc.,VIR,Vir Biotechnology, Inc.股票,Vir Biotechnology, Inc.股票老虎,Vir Biotechnology, Inc.股票老虎国际,Vir Biotechnology, Inc.行情,Vir Biotechnology, Inc.股票行情,Vir Biotechnology, Inc.股价,Vir Biotechnology, Inc.股市,Vir Biotechnology, Inc.股票价格,Vir Biotechnology, Inc.股票交易,Vir Biotechnology, Inc.股票购买,Vir Biotechnology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction